Michael W. Rogers, who has served as CFO of BG Medicine during the past three and half years will be leaving the company. The Board of Directors extends its appreciation for Mr. Rogers who was instrumental in leading the company through its initial public offering and strengthening the company's accounting, periodic reporting and internal control functions.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3
test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing the CardioSCORE
test, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit
The BG Medicine Inc. logo is available at
CONTACT: Dan Quinn
Feinstein Kean Healthcare